Eliminating Tuberculosis by Expanding Molecular Diagnostics
Medikoe Health Expert
Koramangala, bengaluru, karnataka, india, Bengaluru Jul 29, 2021
As tuberculosis continues to lay notable healthcare and socioeconomic burden on the world, the World Health Organization (WHO) has urged the need for expanding the availability of molecular diagnostics to help eradicate the epidemic by 2030.
In 2019, TB affected nearly 1.7 billion people, with an evaluated 10 million new cases and 1.4 million deaths reported. This comprises nearly 815,000 tuberculosis infections in persons living with HIV/AIDS and 208,000 deaths in this population.
Value of TB diagnostics
According to the WHO:
- There is a continuous requirement to scale up capacity to test larger numbers of the specimen if the world is to attain its goal of eliminating TB by 2030.
- High-throughput molecular platforms that include multiple disease-specific tests proved useful during the COVID-19 pandemic and can benefit TB programs globally.
- Merging the suitable diagnostic methods that are extremely efficient and cost-effective in the correct patient setting can enhance access, guide treatment choices and promote quality of life.
- WHO assembled a Guidelines Development Group (GDG) meeting in 2020 to update its diagnostic guidelines on the usage of nucleic acid amplification tests (NAATs) to identify TB and resistance to selected anti-TB agents.
- By raising the number of reliable molecular diagnostic tests available for TB programs in high-burden regions, the update lets Roche give its diagnostic solutions in low- and middle-income countries (LMIC’s)
Roche’s dedication to TB molecular diagnostics
- Roche’s Global Access Program was founded to meet the challenge of universal access to quality healthcare and medical discovery.
- In 2019, the Program was extended to incorporate tuberculosis diagnostic solutions. This allows LMIC’s to get high-quality tests at an affordable price, thereby enabling clinicians to diagnose more patients hastily.
- To expedite these efforts, the company is encouraging current TB program strategies and eradication in downtown settings with a systems integration strategy through multi-disease diagnostics.
- Building centralized diagnostic hubs promotes not only scaling TB program capacity but also facilitating capacity for future pandemics.
- Roche has developed TB diagnostic solutions with an automated, highly-sensitive in vitro diagnostic test that discovers TB infection, while the rapid drug resistance test identifies anti-TB treatment resistance, especially mutations linked with Rifampicin-resistance and Isoniazid-resistance.
- Roche is also operating on a patient-centric disease management digital solution that instructs patients about TB infections, fills the gap on patient follow-up and assures adherence to TB treatment routine through reminders directly delivered to a patient’s mobile phone.
Are you looking for a health expert?
Medikoe is an online platform that allows you to search and connect with the most qualified and experienced doctors near you. Have a query related to health? Get it answered for free within 24 hours only at Medikoe. Download Medikoe's Mobile app and book an appointment with a doctor for free.